Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease

This study has been completed.
Sponsor:
Information provided by:
Erasme University Hospital
ClinicalTrials.gov Identifier:
NCT00610597
First received: January 28, 2008
Last updated: NA
Last verified: January 2008
History: No changes posted
  Purpose

Alcoholic liver disease is characterized by circulating T cell activation and liver T cell infiltration but their phenotype is poorly studied. The aim of the study is to test the hypothesis that the (CD4+ T cell secreting Interleukin-17) Th17 pathway is involved in alcoholic liver disease.


Condition
Alcoholic Liver Disease
Chronic Hepatitis C Virus

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease

Resource links provided by NLM:


Further study details as provided by Erasme University Hospital:

Biospecimen Retention:   Samples Without DNA

plasma and peripheral blood mononuclear cell culture medium.


Enrollment: 49
Study Start Date: January 2005
Study Completion Date: January 2008
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
alcoholic liver disease
2
chronic hepatitis C virus infection

Detailed Description:

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver T cell infiltrates.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

patients of Erasme University Hospital

Criteria

Inclusion Criteria:

  • Alcohol excess intake and suspected liver disease
  • Alcohol excess intake and clinical liver cirrhosis
  • chronic hepatitis C virus infection and suspected liver disease
  • chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion Criteria:

  • bacterial or fungal infection
  • immunosuppressive treatment
  • other causes of liver disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00610597

Locations
Belgium
Hopital Erasme - Dpt of Gastroenterology
Brussels, Belgium
Sponsors and Collaborators
Erasme University Hospital
Investigators
Principal Investigator: Arnaud Lemmers, MD Erasme Hospital, Gastroenterology Dpt
  More Information

No publications provided by Erasme University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Olivier Le Moine, MD, PhD, Erasme University Hospital
ClinicalTrials.gov Identifier: NCT00610597     History of Changes
Other Study ID Numbers: AL-ALD, AL-ALD
Study First Received: January 28, 2008
Last Updated: January 28, 2008
Health Authority: Belgium: Institutional Review Board

Keywords provided by Erasme University Hospital:
liver
alcohol
lymphocyte

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Liver Diseases
Liver Diseases, Alcoholic
Hepatitis C, Chronic
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on April 17, 2014